Tribunal Orders Fresh ALP Analysis for Transfer Pricing Dispute

The Tribunal set aside the matter to the AO/TPO for a fresh adjudication on both issues regarding the exclusion of Celestial Labs Ltd. and inclusion of Tonira Pharma Ltd. as comparables for determining the Arm's Length Price (ALP). The AO/TPO was instructed to conduct a detailed analysis of the financial statements of both companies, excluding the impact of extraordinary events such as IPO and inventory attachment, to accurately assess their comparability. The Revenue's appeal was allowed for statistical purposes, emphasizing the importance of providing the assessee with a fair opportunity to present evidence and arguments in the reassessment process.

---

---

Issues Involved:
1. Exclusion of Celestial Labs Ltd. from the comparables for determining the ALP.
2. Inclusion of Tonira Pharma Ltd. in the final set of comparables for determining the ALP.

Issue-wise Detailed Analysis:

1. Exclusion of Celestial Labs Ltd. from the comparables for determining the ALP:

The Revenue's primary contention was that the CIT(A) erred in excluding Celestial Labs Ltd. from the comparables on the grounds of abnormal profit levels and different functional profiles. The CIT(A) had directed the exclusion of Celestial Labs Ltd., noting that the company reported an abnormal profit margin of 87.94% and was involved in different functional activities compared to the assessee. The TPO had included Celestial Labs Ltd. as a comparable, asserting that it was engaged in clinical research, which aligned with the assessee's product development activities.

The Tribunal observed that the financial data of Celestial Labs Ltd. indicated significant profits in the years preceding the assessment year, but a deeper analysis of the financial statements was necessary to understand the reasons behind the abnormal profits. The Tribunal noted that the company had undergone an Initial Public Offering (IPO) during the relevant period, which could have influenced its profitability. The Tribunal directed the AO/TPO to re-examine the financial statements of Celestial Labs Ltd., excluding the impact of the IPO and other extraordinary events, to determine its appropriateness as a comparable.

2. Inclusion of Tonira Pharma Ltd. in the final set of comparables for determining the ALP:

The Revenue challenged the CIT(A)'s decision to include Tonira Pharma Ltd. as a comparable, arguing that it was a loss-making company with a negative PLI of (-)16.90%. The CIT(A) had directed the inclusion of Tonira Pharma Ltd., stating that the presence of waste disposal systems was not a valid reason for exclusion and that the company was otherwise functionally comparable.

The Tribunal noted that Tonira Pharma Ltd. had faced extraordinary events, including the attachment of its inventory by the Excise and Customs Department, which affected its profitability. The Tribunal emphasized that the impact of such extraordinary events should be excluded when computing the PLI for benchmarking purposes. The Tribunal directed the AO/TPO to re-evaluate the financial statements of Tonira Pharma Ltd., excluding the impact of the extraordinary events, to determine its suitability as a comparable.

Conclusion:

The Tribunal set aside the matter to the AO/TPO for a fresh adjudication on both issues. The AO/TPO was directed to provide the assessee with a proper opportunity to present evidence and arguments. The Tribunal emphasized the need for a detailed analysis of the financial statements of both Celestial Labs Ltd. and Tonira Pharma Ltd., excluding the impact of extraordinary events, to accurately determine their comparability for computing the ALP of the international transactions. The appeal of the Revenue was allowed for statistical purposes.

---